Collegium Pharmaceutical, Inc. reaffirmed earnings guidance for the full year 2024. For the year, the company expects Product Revenues to be between $580.0 million to $595.0 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.47 USD | -3.56% | +3.08% | +5.49% |
May. 13 | Collegium Pharmaceutical Launches $35 Million Accelerated Share Repurchase Program | MT |
May. 10 | Needham Downgrades Collegium Pharmaceutical to Hold From Buy | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.49% | 1.06B | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- COLL Stock
- News Collegium Pharmaceutical, Inc.
- Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024